Related references
Note: Only part of the references are listed.Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus
Yuanmei Zhu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor
Danwei Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models
Huihui Chong et al.
JOURNAL OF VIROLOGY (2018)
Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket
Xiujuan Zhang et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2018)
Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus
Huihui Chong et al.
JOURNAL OF VIROLOGY (2018)
A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus
Shengwen Xiong et al.
JOURNAL OF VIROLOGY (2017)
Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition
Xiaohui Ding et al.
JOURNAL OF VIROLOGY (2017)
A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity
Huihui Chong et al.
JOURNAL OF VIROLOGY (2017)
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Christopher Sorli et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Development of potent and long-acting HIV-1 fusion inhibitors
Huihui Chong et al.
AIDS (2016)
Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket
Huihui Chong et al.
AIDS (2015)
Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target
Zonglin Qiu et al.
AIDS (2015)
Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket
Yang Su et al.
JOURNAL OF VIROLOGY (2015)
Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket
Yang Su et al.
JOURNAL OF VIROLOGY (2015)
Improvement of HIV fusion inhibitor C34 efficacy by membrane anchoring and enhanced exposure
Marcelo T. Augusto et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance
Huihui Chong et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Synthesized Peptide Inhibitors of HIV-1 gp41-dependent Membrane Fusion
Yuxian He
CURRENT PHARMACEUTICAL DESIGN (2013)
Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1
Huihui Chong et al.
FASEB JOURNAL (2013)
Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1
Avraham Ashkenazi et al.
FASEB JOURNAL (2012)
Discovery of Critical Residues for Viral Entry and Inhibition through Structural Insight of HIV-1 Fusion Inhibitor CP621-652
Huihui Chong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor Sifuvirtide
Xue Yao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Structural Basis of Potent and Broad HIV-1 Fusion Inhibitor CP32M
Xue Yao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
The M-T Hook Structure Is Critical for Design of HIV-1 Fusion Inhibitors
Huihui Chong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Resistance of Human Immunodeficiency Virus Type 1 to a Third-Generation Fusion Inhibitor Requires Multiple Mutations in gp41 and Is Accompanied by a Dramatic Loss of gp41 Function
Dirk Eggink et al.
JOURNAL OF VIROLOGY (2011)
Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain
Yael Wexler-Cohen et al.
FASEB JOURNAL (2010)
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Xueling Wu et al.
SCIENCE (2010)
HIV-1 Entry, Inhibitors, and Resistance
Michael A. Lobritz et al.
VIRUSES-BASEL (2010)
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency
Paolo Ingallinella et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Membrane-Anchored HIV-1 N-Heptad Repeat Peptides Are Highly Potent Cell Fusion Inhibitors via an Altered Mode of Action
Yael Wexler-Cohen et al.
PLOS PATHOGENS (2009)
Conserved Salt Bridge between the N- and C-Terminal Heptad Repeat Regions of the Human Immunodeficiency Virus Type 1 gp41 Core Structure Is Critical for Virus Entry and Inhibition
Yuxian He et al.
JOURNAL OF VIROLOGY (2008)
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: Implications for designing novel anti-HIV fusion inhibitors
Yuxian He et al.
JOURNAL OF VIROLOGY (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains
Yuxian He et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
HIV drug development: the next 25 years
Charles Flexner
NATURE REVIEWS DRUG DISCOVERY (2007)
Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: Importance of fatty acid length, polarity, and bulkiness
Kjeld Madsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition
Yael Wexler-Cohen et al.
FASEB JOURNAL (2007)
Conserved residue Lys574 in the cavity of HIV-1 gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry
Yuxian He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Structural analysis and assembly of the HIV-1 gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at-interface sequence
Maier Lorizate et al.
BIOCHEMISTRY (2006)
Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120
SW Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
T Matthews et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor
W Yuan et al.
JOURNAL OF VIROLOGY (2004)
C-terminal octylation rescues an inactive T20 mutant - Implications for the mechanism of HIV/simian immunodeficiency virus-induced membrane fusion
SG Peisajovich et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
JP Lalezari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
JD Reeves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor
CA Derdeyn et al.
JOURNAL OF VIROLOGY (2001)
Mode of action of an antiviral peptide from HIV-1 -: Inhibition at a post-lipid mixing stage
Y Kliger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
CA Derdeyn et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
